Non-Small Cell Lung Cancer

The FDA approval of amivantamab-vmjw (Rybrevant) in combination with chemotherapy is the first targeted treatment to cut disease progression risk for EGFR-positive non–small cell lung cancer (NSCLC).

Here we conclude our discussion with David P. Carbone, MD, PhD, The Ohio State University, by addressing the importance of both advocacy for and education on biomarker testing in the lung cancer space.

Developers anticipate releasing full efficacy results from the phase 2 THIO-101 trial later this year.

This newest approval for amivantamab is the second approval in 6 months for the EGFR and MET bispecific antibody.

Measures of systemic inflammation used for the liver, including C-reactive protein-albumin ratio and modified Glasgow prognostic score, demonstrated prognostic value in non–small cell lung cancer (NSCLC).

In part 1 of our interview with David P. Carbone, MD, PhD, The Ohio State University, he addressed why it is important to conduct biomarker testing in both lung cancer overall and non–small cell lung cancer more specifically.

Patients with non-small cell lung cancer (NSCLC) can use lazertinib in combination with amivantamab as a first-line treatment.

This investigation was conducted among older, frail patients, a population typically underrepresented in clinical trials.

David P. Carbone, MD, PhD, director of the thoracic oncology center at The Ohio State University in Columbus, discusses the importance of biomarker testing in both lung cancer overall and non–small cell lung cancer specifically.

New therapies to treat EGFR-mutated non–small cell lung cancer (NSCLC) following EGFR tyrosine kinase inhibitors (TKIs) are needed to address EGFR TKI resistance after osimertinib.

Visceral pleural invasion of non–small cell lung cancer (NSCLC) was investigated in this analysis for its potential to predispose patients to worse survival outcomes and greater chances of disease recurrence.

Should the FDA require that new trial design proposals for perioperative regimens for resectable non–small cell lung cancer (NSCLC) include adequate within trial assessment?

Patients with unresectable stage III non–small cell lung cancer (NSCLC) who received atezolizumab before and after chemoradiation therapy (CRT) had both safe and effective results.

Jason Porter, MD, analyzes the TROPION-Lung05 trial investigating Dato-DXd in non-small cell lung cancer patients with brain metastases, emphasizing crucial insights from this pivotal study.

For this analysis, investigators were interested in patient non–small cell lung cancer (NSCLC)–related outcomes from antibiotic administration before immunotherapy alone or immunotherapy and chemotherapy.

A key opinion leader examines the combination therapy of amivantamab and lazertinib in the CHRYSALIS-2 study for treatment-naïve patients or those with 2 or more prior lines of therapy, and its potential implications for non-small cell lung cancer treatment.

Jason Porter, MD, analyzes critical insights from the 2024 ASCO Annual Meeting presentation on progression-free survival data from the LAURA phase 3 trial, which evaluated osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer who did not progress after definitive chemoradiotherapy.

In this final segment of our interview with Ontada's Jessica K. Paulus, ScD, she explains how her team's data presented at the American Society of Clinical Oncology annual conference may translate to the real world.

Patients were satisfied with receiving their lung cancer screening (LCS) pulmonary nodule results via letter and considered the amount of information provided in the letter appropriate.

This new analysis incorporated 1997-2013 data on patients with a history of surgical resection of stage IIIA-N2 non-small cell lung cancer (NSCLC) and their postop complications to evaluate the possibility of better identifying future surgical candidates.

In our ongoing interview with Jessica K. Paulus, ScD, Ontada, she explains potential drivers behind changing trends in care for lung cancer that may have been influenced by the COVID-19 pandemic.

Investigators compared cost-effectiveness of the KRAS inhibitor sotorasib against the taxane docetaxel in the second line for non–small cell lung cancer (NSCLC).

In part 3 of our interview, Jessica K. Paulus, ScD, Ontada, addresses the importance of understanding data sources and their impact on clinical research.

The complete response letter (CRL) was not related to safety or efficacy data, but was a result of inspection findings at a third-party manufacturing facility.

“The screening victory there is going to take some more time to show its benefit at the population level,” notes Jessica K. Paulus, ScD. “Some of these things are just going to be reductions in mortality that we have to wait to observe over time.”